How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Julie R. Gralow, Allan Lipton, Alison T. Stopeck

Research output: Contribution to journalLetter

2 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)3591-3592
Number of pages2
JournalJournal of Clinical Oncology
Volume29
Issue number26
DOIs
StatePublished - Sep 10 2011

Fingerprint

Bone Density Conservation Agents
Bone Neoplasms
Osteoclasts
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{97202926f60148e59b11fcd3bc65c2b5,
title = "How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?",
author = "Gralow, {Julie R.} and Allan Lipton and Stopeck, {Alison T.}",
year = "2011",
month = "9",
day = "10",
doi = "10.1200/JCO.2011.36.5759",
language = "English (US)",
volume = "29",
pages = "3591--3592",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer? / Gralow, Julie R.; Lipton, Allan; Stopeck, Alison T.

In: Journal of Clinical Oncology, Vol. 29, No. 26, 10.09.2011, p. 3591-3592.

Research output: Contribution to journalLetter

TY - JOUR

T1 - How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

AU - Gralow, Julie R.

AU - Lipton, Allan

AU - Stopeck, Alison T.

PY - 2011/9/10

Y1 - 2011/9/10

UR - http://www.scopus.com/inward/record.url?scp=80052981884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052981884&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.36.5759

DO - 10.1200/JCO.2011.36.5759

M3 - Letter

C2 - 21844502

AN - SCOPUS:80052981884

VL - 29

SP - 3591

EP - 3592

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -